BACKGROUND: The aim of this study was to determine the concentration of cytokine IL-6 in correlation with its soluble receptor sIL-6R in the serum and CSF of MS patients. MATERIAL AND METHODS: The study group consisted of 52 MS patients in clinical stage 2-7 according to the Kurtzke Scale (mean 3.6 +/- 1.8); the disease duration ranged from 2 to 22 years. The levels of interleukin-6 and sIL-6R in serum and CSF were determined using commercial ELISA kits. RESULTS: An significant increase of IL-6 (p=0.03) was found in the serum of MS patients (12.1 +/- 1.8 pg/ml) in comparison to the control group (6.6 +/- 4.5 pg/ml). The concentration of IL-6 in the CSF of MS patients was 13.4 +/- 1.77 pg/ml, and in the majority of patients was higher than in the serum. The highest mean IL-6 concentrations in serum and CSF were found in patients with a longer disease duration, although the differences were not statistically significant. We found some degree of dependence between the serum IL-6 concentration and the level of disability on the Kurtzke scale. The concentrations of sIL-6R in serum (34.0 +/- 39.0 pg/ml) and cerebrospinal fluid (1.4 +/- 3.3 pg/ml) were significantly higher in MS patients than in the controls. CONCLUSIONS: IL-6 and its soluble receptors are involved in a complex immunological reaction that is characteristic for MS. However, the significant differences in the results obtained here from those reported in other studies make it rather unlikely that IL-6 and its receptors could be used as surrogate markers of MS activity.
BACKGROUND: The aim of this study was to determine the concentration of cytokine IL-6 in correlation with its soluble receptor sIL-6R in the serum and CSF of MSpatients. MATERIAL AND METHODS: The study group consisted of 52 MSpatients in clinical stage 2-7 according to the Kurtzke Scale (mean 3.6 +/- 1.8); the disease duration ranged from 2 to 22 years. The levels of interleukin-6 and sIL-6R in serum and CSF were determined using commercial ELISA kits. RESULTS: An significant increase of IL-6 (p=0.03) was found in the serum of MSpatients (12.1 +/- 1.8 pg/ml) in comparison to the control group (6.6 +/- 4.5 pg/ml). The concentration of IL-6 in the CSF of MSpatients was 13.4 +/- 1.77 pg/ml, and in the majority of patients was higher than in the serum. The highest mean IL-6 concentrations in serum and CSF were found in patients with a longer disease duration, although the differences were not statistically significant. We found some degree of dependence between the serum IL-6 concentration and the level of disability on the Kurtzke scale. The concentrations of sIL-6R in serum (34.0 +/- 39.0 pg/ml) and cerebrospinal fluid (1.4 +/- 3.3 pg/ml) were significantly higher in MSpatients than in the controls. CONCLUSIONS:IL-6 and its soluble receptors are involved in a complex immunological reaction that is characteristic for MS. However, the significant differences in the results obtained here from those reported in other studies make it rather unlikely that IL-6 and its receptors could be used as surrogate markers of MS activity.
Authors: V Fominykh; L Brylev; V Gaskin; R Luzin; A Yakovlev; I Komoltsev; I Belousova; A Rosliakova; A Guekht; N Gulyaeva Journal: Metab Brain Dis Date: 2019-07-02 Impact factor: 3.584
Authors: Vera Fominykh; Anna Vorobyeva; Mikhail V Onufriev; Lev Brylev; Maria N Zakharova; Natalia V Gulyaeva Journal: J Clin Neurol Date: 2018-05-31 Impact factor: 3.077
Authors: Paula Sanchis; Olaya Fernández-Gayol; Gemma Comes; Anna Escrig; Mercedes Giralt; Richard D Palmiter; Juan Hidalgo Journal: Cells Date: 2020-01-31 Impact factor: 6.600